These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 15957963)

  • 1. The role of taxanes in the treatment of breast cancer.
    Nabholtz JM; Gligorov J
    Expert Opin Pharmacother; 2005 Jun; 6(7):1073-94. PubMed ID: 15957963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?
    Nabholtz JM; Tonkin K; Smylie M; Au HJ; Lindsay MA; Mackey J
    Expert Opin Pharmacother; 2000 Jan; 1(2):187-206. PubMed ID: 11249542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the use of taxanes in the adjuvant therapy of breast cancer.
    Nabholtz JM; Vannetzel JM; Llory JF; Bouffette P
    Clin Breast Cancer; 2003 Aug; 4(3):187-92. PubMed ID: 14499011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of taxanes in treatment of breast cancer].
    Gorbunova VA; Besova NS
    Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
    [No Abstract]   [Full Text] [Related]  

  • 7. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxane therapy for early stage breast cancer.
    Nabholtz JM; Gligorov J
    Womens Health (Lond); 2006 Jan; 2(1):99-114. PubMed ID: 19803931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ongoing US cooperative group trials using taxanes in the adjuvant setting.
    Davidson NE
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S53-8. PubMed ID: 12435293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
    Bullock K; Blackwell K
    Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
    Ravdin PM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and docetaxel in the treatment of breast cancer.
    Saloustros E; Mavroudis D; Georgoulias V
    Expert Opin Pharmacother; 2008 Oct; 9(15):2603-16. PubMed ID: 18803448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel in the treatment of breast cancer: an update on recent studies.
    Nabholtz JM; Reese DM; Lindsay MA; Riva A
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):28-34. PubMed ID: 12170449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of taxanes in the adjuvant treatment of early stage breast cancer.
    Piccart M
    Breast Cancer Res Treat; 2003; 79 Suppl 1():S25-34. PubMed ID: 12868803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
    Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
    J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxanes in the adjuvant treatment of breast cancer: why not yet?
    Piccart MJ; Lohrisch C; Duchateau L; Buyse M
    J Natl Cancer Inst Monogr; 2001; (30):88-95. PubMed ID: 11773299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
    Nabholtz JM; Riva A
    Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S7-14. PubMed ID: 11970739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
    Bedard PL; Di Leo A; Piccart-Gebhart MJ
    Nat Rev Clin Oncol; 2010 Jan; 7(1):22-36. PubMed ID: 19997076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
    Ravdin PM
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.